Viking Therapeutics (VKTX) Cash & Equivalents (2014 - 2026)

Viking Therapeutics (VKTX) has 13 years of Cash & Equivalents data on file, last reported at $118.1 million in Q1 2026.

• For the quarter ending Q1 2026, Cash & Equivalents rose 211.32% year-over-year to $118.1 million; the trailing twelve-month figure through Mar 2026 stood at $118.1 million (up 211.32% YoY), and the FY2025 full-year result was $165.8 million, up 521.57% from the prior year.
• Cash & Equivalents slipped to $118.1 million in Q1 2026, from $165.8 million in the prior quarter.
• In the past five years, Cash & Equivalents ranged from a high of $195.6 million in Q1 2024 to a low of $18.4 million in Q1 2023.
• A 5-year average of $79.4 million and a median of $50.3 million in 2024 frame the typical range for Cash & Equivalents.
• Across the five-year window, Cash & Equivalents jumped 1629.43% in 2022 and plunged 89.72% in 2023, its largest moves.
• Tracing VKTX's Cash & Equivalents over 5 years: stood at $36.6 million in 2022, then jumped by 51.55% to $55.5 million in 2023, then sank by 51.95% to $26.7 million in 2024, then surged by 521.57% to $165.8 million in 2025, then declined by 28.76% to $118.1 million in 2026.
• Business Quant data shows VKTX's Cash & Equivalents at $118.1 million in Q1 2026, $165.8 million in Q4 2025, and $100.4 million in Q3 2025.